Introduction
In addition to the role of mitochondria in energy production and reactive oxygen species production, recent interest has increasingly centred on their role in apoptosis (Green and Reed, 1998) . It is the modulation of these processes and their relationship to cell death and survival that has prompted recent investigations into the role of mitochondria in tumorigenesis (Cavalli and Liang, 1998) . A small number of studies have demonstrated somatic mutations in colorectal and gastric carcinomas (Alonso et al., 1997; Burgart et al., 1995; Polyak et al., 1998) . However, most studies which have focused on breast, thyroid and renal neoplasms have been limited by small sample sizes and insensitive or incomplete screening techniques and have found con¯icting results (Bianchi et al., 1995; Ebner et al., 1991; Horton et al., 1996; Johnson et al., 1996; Muller-Hocker et al., 1998; Tallini et al., 1994; Welter et al., 1989) .
Oncocytic tumours, because of their large abundance of mitochondria, are of particular interest. Although the thyroid is one of the most common sites of oncocytic tumours, of particular note is that all thyroid carcinomas, not just HuÈ rthle cell tumours, have increased numbers of mitochondria (Stefaneanu and Tasca, 1979) . Studies of these tumours as well as mitochondrial diseases have led to several hypotheses including one in which defects in oxidative phosphorylation are sensed by mitochondrial regulatory mechanisms, producing a compensatory response of increased mitochondrial proliferation and/or gene expression (Ebner et al., 1991; Wallace, 1992) .
Mutation analyses of mtDNA in thyroid tumours have been limited to date. Prior studies of tumours of the thyroid have been limited in size and scope (Ebner et al., 1991; Johnson et al., 1996; MullerHockner et al., 1998; Tallini et al., 1994) . The four studies combined have reported on only 19 cases of thyroid tumours; of these 19, seven were found to have mtDNA sequence variation and 12 were not. Given the size of the mitochondrial genome, the majority of these studies (Ebner et al., 1991; MullerHocker et al., 1998; Tallini et al., 1994) only targeted a few selected areas of the genome and relied on restriction analysis. Because of practical technical limitations, there has yet to be a study that systematically analyses the coding regions of the mitochondrial genome in sporadic adult human thyroid tumours comparing dierent pathologies as well as region-matched population controls.
The entire mitochondrial genome is circular and totals 16.6 kb in length. It encodes 13 polypeptide genes, the 12S and 16S RNA genes, and 22 tRNAs which are involved in oxidative phosphorylation (OXPHOS). OXPHOS comprises ®ve multisubunit complexes (I ± V) and all are encoded by a combination of nuclear and mtDNA except for complex II, which is only encoded by nuclear genes. Complex I (NADH dehydrogenase) contains 43 subunits, seven of which are encoded by mtDNA genes (ND1, 2, 3, 4, 4L, 5 and 6) (Wallace, 1999) . One subunit of Complex III [cytochrome b (CYT B)], three subunits of Complex IV (COI, II and III) and two subunits of Complex V (ATPase 6 and 8) are encoded by mtDNA genes (Wallace, 1999) .
Recent development of two-dimensional gene scanning (TDGS) to analyse critical areas, i.e. all areas of known pathogenesis, of the mitochondrial genome has prompted us to conduct a comprehensive examination for mtDNA mutations and sequence variation in thyroid tumours. Although only displaying 25% of the mitochondrial genome, this method targets multiple areas including all protein encoding genes, as well as rRNAs and 19 of 22 (86%) tRNAs residing in the genome (Table 1) . It is also able to detect a heteroplasmy rate as low as 1% . Using TDGS, we have successfully scanned 21 cases of thyroid tumours, six cases of non-neoplastic thyroid pathology, 30 population controls, nine foetal thyroid tissues and nine foetal tissues of a second type either kidney or liver. We have identi®ed three somatic mutations, all in papillary thyroid carcinomas (PTCs) (19% of all carcinomas; 23% of all PTCs). In addition, we have found 66 sequence variants, representing 39 distinct variations, present in pathological thyroid samples as well as their paired normal thyroid tissues.
Results
Using TDGS, we analysed the mitochondrial genome from 27 paired pathologic and normal thyroid samples, 30 leukocyte samples from controls derived from the normal population, and nine paired foetal thyroid and non-thyroid tissues (Figures 1 and 2) . Interestingly, only the PTCs were found to have somatic mtDNA mutations. Among 13 PTCs, there were three somatic homoplasmic mtDNA mutations (23%; Table 2a,c). In one PTC (multicentric with 0.4 cm nodules), a somatic 7521 G4A mutation was found in the gene encoding tRNA Asp . In a second PTC (low-grade follicular variant), a somatic 10398 A4G was found, which resulted in T113A in the ND3 gene. In the third (1.1 cm PTC), a somatic 15179 G4A, predicted to result in V144M, was found in CYT B. The latter had a lymph node with metastatic PTC. The former two demonstrated no evidence of lymph node metastasis or vascular invasion. None exhibited HuÈ rthle cell changes and none of the individuals had a history of familial thyroid disease. In fact, retrospectively, two individuals reported a positive family history of thyroid disease (1 HCA, 1 PTC) and neither had any mitochondrial variants identi®ed.
Among all samples combined, both pathologic thyroid tissues and normal controls, we identi®ed a total of 136 sequence variants, representing 51 distinct mtDNA variations (Table 2 ). Twenty-one of the 51 distinct variants have not been previously reported, according to the mitochondrial database, MITOMAP (http://www.gen.emory.edu/mitomap.html). Of these 51 dierent variations, 16 were predicted to alter the amino acid sequence of the encoded proteins; 24 were predicted to be neutral; eight aected tRNA or rRNA genes, and three were in non-coding regions between genes. All were single nucleotide base substitutions.
Of the 39 sequence variants found in the thyroid samples, 24 (60%) were unique to these samples. That is, they were not found in the mtDNA derived from peripheral blood leukocytes from the normal adult population or from the paired foetal tissue controls (Table 2) . Ninety-®ve per cent (38 of 40) of these variants occurred homoplasmically. One variant, 8270 C4G, which was also homoplasmic, was found in normal thyroid but not its corresponding tumour. The remaining variants were either found in both the Since most variants found in the thyroid samples, excluding the somatic mutations mentioned above, were found in both the tumour and corresponding normal adjacent thyroid tissues, we wanted to con®rm that this was not a tissue-speci®c phenomenon. We therefore compared paired foetal thyroid and a second organ obtained from therapeutic abortions. All mtDNA variants, which were identi®ed in foetal thyroid tissues, were also found in the second paired non-thyroid tissue.
As multiple sequence variants (1 ± 6 per sample) were identi®ed in the pathologic tissues studied as well as normal population and foetal tissue controls, we sought to determine whether the distribution or quantity of variants that were found in the pathologic tissues diered from those in the control populations. The distributions of the number of mtDNA sequence variants were compared using the Kruskal-Wallis test (Siegel and Castellan, 1988) (Table 3) . Comparisons between dierent pathologic sample types and dierent variant types were made. The Kruskal-Wallis test compares the distribution of the number of variants per sample, and is most powerful when populations have similarly shaped distributions that are shifted with respect to each other. In order to further examine the dierences in the distribution of variants among our samples that were identi®ed by the Kruskal-Wallis tests, we compared the mean number of variants per sample (Table 4 ) between dierent pathologies. Given the type of data and small sample sizes, no statistical tests were performed when comparing the means.
Normal population samples vs foetal tissues
No signi®cant dierence was identi®ed in the distribution of the number of variants between the 30 normal blood samples and the nine foetal thyroid tissue samples. They were, therefore, considered as a single group of normal controls' (hereafter collectively referred to as controls') comprising a total of 39 samples.
Pathologic thyroid samples vs controls
When the sequence variants in the 27 cases with thyroid pathology were compared to those of the 39 controls, a signi®cant dierence was observed in the distribution of variants (P=0.05; Table 3 ). Speci®cally, cases with thyroid pathology appeared to have more variants than controls. There also appeared to be nearly two times as many variants per sample on average among the aggregate abnormal samples compared to the normal samples (2.556 versus 1.385; Table 4 ).
This dierence between the thyroid samples and controls was most likely due to the signi®cant dierence between carcinomas and controls (P=0.002; Table 3 ). The distributions of all variant types between carcinomas and controls diered signi®cantly. There was no dierence in distributions between either benign or non-neoplastic samples compared to controls.
Carcinoma cases vs adenoma cases
Interestingly, carcinomas (n=16) and adenomas (n=5) diered signi®cantly only in their distributions Table 3 ). There was a fourfold dierence in the mean number of neutral coding variants that were identi®ed in the adenomas (0.200) versus carcinomas (0.875; Table 4 ). Only one of ®ve (20%) adenoma samples had a neutral variant in a coding region, compared to 10 of 16 (63%) in the carcinoma samples.
Neoplastic vs non-neoplastic thyroid pathology
Although there was limited power to detect such dierences with the small sample sizes available, we found that there were no signi®cant dierences between the distribution of total variants in the neoplastic (carcinomas plus adenomas) (n=21) and non-neoplas- tic (n=6) thyroid samples. However, there was some evidence that these sample groups may dier in the distribution of the number of variants in the genes encoding tRNAs and tRNAs (P=0.05; Table 3 ). Speci®cally, none of the non-neoplastic samples had any variants in the RNA encoding genes, while 11 of 21 (52%) neoplastic samples had at least one variant with an average of 0.857 (Table 4) variants per neoplastic sample.
Mean number of variants in electron transport chain
In order to examine whether the mtDNA sequence variants which were identi®ed were possibly occurring at preferential`hotspots' in the protein encoding genes of the electron transport chain, we also computed the mean number of variants per sample by complex (Table 5 ). Complex I (NADH dehydrogenase) had the greatest dierence in the mean number of coding variants between normal (0.513) and pathologic samples (1.074). Although there was also a twofold dierence in the mean number of variants per sample in complex 4, the total number of variants was considerably lower (0.179 for normal samples versus 0.370 for abnormal samples).
Discussion
Systematic examination of the mitochondrial genome has led us to uncover three somatic mutations in PTCs and a signi®cant dierential distribution of mtDNA variants in cases with malignant thyroid pathology versus normal controls. Although confounded by a small sample size in benign and non-neoplastic thyroid pathology, the ®nding of signi®cant dierential neutral coding and RNA variant distributions between benign and malignant and between non-neoplastic and neoplastic thyroid cases, respectively, is also interesting.
While ®nding somatic mtDNA mutations in PTCs is novel, these mutations occur only in a minority of tumours, albeit a signi®cant minority. However, whether the 23% mutation frequency among PTCs is an underestimate is not known. Although TDGS targets all known pathogenic areas of the mitochondrial genome, it only examines segments of speci®c genes (Table 1) . Therefore, variants or mutations lying outside these segments would be missed. In addition, because the tissues were dissected based on their gross pathologies and because TDGS is exceedingly sensitive in detecting mismatch, it is possible that a small amount of tumour contamination of normal thyroid tissue could result in a false positive. Nonetheless, despite this caveat, the ®nding of somatic mtDNA mutations in a subset of sporadic PTCs is signi®cant and is consistent with the hypothesis that these represent later events, events related to tumour progression and not necessarily initiation.
All three somatic mutations found in the PTCs are missense mutations. As such, it is dicult to assign functionality to missense mutations, and this is particularly so for mtDNA alterations. In general somatic missense mutations noted in the tumour and not the corresponding germline/transmitted DNA from the same individual usually suggests pathogenecity. Further, the majority of heritable mtDNA mutations found in neurodegenerative diseases are missense (reviewed by Simon and Johns, 1999) . Two of the three somatic mutations identi®ed in PTCs (10398 A4G in ND3 and 7521 G4A in tRNA Asp ) were also found in the heritable (not somatic) mitochondrial genome of other individuals with non-PTC tumours as well as normal controls. This suggests that when these mutations are somatic, they are speci®c to PTCs and that the 10398A4G and 7521G4A variants might not be totally innocuous despite being found in the transmitted mitochondrial genome of other individuals. One might speculate that these somatic mtDNA mutations are low penetrance modi®ers of tumour risk which, along with other mtDNA alterations may augment this risk. Alternatively, it is also possible that these represent mtDNA damage from oxidative stress. In other words, cause and eect cannot be separated at present. A recent comprehensive study demonstrating somatic mitochondrial mutations in colorectal tumours found that, of 88 novel sequence variants, only 12 were somatic (Polyak et al., 1998) . This, together with prior studies which demonstrated the presence of mtDNA variants in both tumour and adjacent tumour tissue (Bianchi et al., 1995; Johnson et al., 1996) and our own ®ndings, prompted us to hypothesise that non-somatic variants may also play a role in tumorigenesis. Although additionally supported by our ®ndings that there were signi®cant dierences in the distribution of the number of variants between, for example, carcinomas and controls, we were, nonetheless, concerned that these non-somatic variants represented either tissue speci®c variants or an admix of tumour and normal cells. We demonstrated that this was unlikely since: (1) there were no dierences in the distribution of variants among nine distinct sets of foetal thyroid tissue paired with another non-thyroid tissue (kidney or liver) from the same; and (2) the distribution in the foetal tissues was similar to that from peripheral blood leukocyte mtDNA from the adult normal control population. Hence, our observations are likely speci®c for cases with thyroid pathology.
Because thyroid tissues do have high energy requirements (Wallace, 1999) , should the accumulation of certain non-somatic variants aect the eciency of OXPHOS, individuals harbouring those variants may be predisposed, in some way, to develop thyroid neoplasia. For example, if increasing numbers of mtDNA variants, particularly seen in the carcinoma cases in our study, cause alterations in OXPHOS, then our data would suggest that these speci®c variants might be involved in or associated with tumour progression. This would be in agreement with the recently proposed model in colorectal tumours where somatic mitochondrial mutations, together with other polymorphic variations in mtDNA, would result in subtle changes that would generate slightly higher levels of reactive oxygen species, thereby producing an environment conducive to cell proliferation (Polyak et al., 1998) . This, in addition to the high mutation rate of mtDNA (10 times that of nuclear DNA) (Wallace, 1994) and ®ndings that MnSOD levels decrease in tumour cells (Oberley and Oberley, 1988) , suggests that tumour cells and speci®cally mtDNA in these cells are especially susceptible to free radical damage. Therefore, whether the accumulation of mtDNA variants overall is correlated with thyroid tumorigenesis and/or progression, or is the result of the neoplastic process remains to be investigated. Study of these variants and their possible functional impact on OXPHOS may help us better understand the role of mitochondria in tumorigenesis.
Materials and methods

Tissues
Twenty-one tumours (one HuÈ rthle cell adenoma, four follicular adenomas, 13 PTCs, one follicular carcinoma, one insular carcinoma, one medullary carcinoma) and six noncarcinomatous pathologic samples (three cases of multinodular hyperplasia and three cases of Hashimoto's thyroiditis) and their corresponding normal adjacent tissue were obtained at the time of surgery, carefully dissected by expert pathologists, and snap frozen.
Peripheral blood leukocytes obtained from 30 random normal adult volunteers were used for a control population. These specimens were stripped of all identi®ers for complete anonymization. In addition, nine anonymized paired foetal thyroid tissues and kidney or liver tissues were used as controls for analysing the tissue speci®city and frequency of variants found. All foetal tissues were obtained from therapeutic, and therefore, most likely normal, ®rst trimester abortions. All tissues were obtained according to Human Research Committee protocols (Brigham and Women's Hospital, Boston, MA, USA).
DNA isolation
DNA was extracted from frozen pathologic and normal thyroid tissue pairs, and foetal tissues, using the QIAmp Tissue Kit (Qiagen Inc., Valencia, CA, USA). DNA was extracted from peripheral leukocytes using standard protocols (Ausubel, 1994 (Ausubel, ± 1998 . These protocols result in the extraction of both genomic and mtDNA.
PCR amplification
All primers used were obtained from Gibco ± BRL (Rockville, MD, USA) and were identical to those previously described . A PTC-200 thermal cycler (MJ Research, Watertown, MA, USA) was used. Long-distance PCR products of 16.4 kb in length were obtained using the LA PCR Kit (Takara, Japan). Multiplex short PCRs of two multiplex groups (I and II) and singleplex short PCRs were carried out as previously described .
Because of the potential for the presence of homoplasmy, both groups of multiplex PCR fragments were also subjected to a heteroduplexing reaction with a positive`normal' control, i.e. pooled human DNA (Promega, Madison, WI, USA), prior to electrophoresis. The heteroduplexing reaction was carried out as previously described .
TDGS and DGGE
For TDGS, a semi-automated Two Dimensional Gene Scanning System (TDGS-4002, C.B.S. Scienti®c Co., Solana Beach, CA, USA) was used (Dhanda et al., 1998) . This TDGS was similar to the DGGE-4000 apparatus previously described ; it possessed the additional ability to run the ®rst (horizontal) and second (vertical) dimensions sequentially without gel manipulation. This obviated both the needs to excise bands from the ®rst dimension and for a second gel for the second dimension.
Similar to , a 1 mm thick 10% polyacrylamide (acrylamide : bisacrylamide=37.5 : 1) gel with a urea formamide (UF) gradient between 25 and 55% (100% UF is 7.0 M urea and 40% formamide) was used. The 55% UF solution also contained 10% glycerol. Gradient gels were created by mixing the two solutions (25% UF and 55% UF) in a linear gradient former (Gibco ± BRL, Rockville, MD, USA). After polymerization of the gradient gel, a nondenaturing stacking gel comprised of 10% polyacrylamide was poured on top of the gradient gel. A TDGS comb was then inserted.
After heteroduplexing, 5 ml each of multiplex groups I and II from a single sample were combined and mixed with loading buer (0.25% xylene cyanol, 0.25% bromophenol blue, 15% Ficoll, and 100 mM Na 2 EDTA) as previously described . Electrophoresis for the ®rst (horizontal) dimension was conducted at 508C for 3.5 h at 250 V in 0.56TAE (506TAE=2 M Tris-Acetate and 50 mM EDTA, Gibco ± BRL, Rockville, MD, USA). For the second (vertical dimension), the temperature was increased to 608C and then electrophoresis was carried out for 13.5 h at 100 V. Gel-based two-dimensional`®ngerprints' were visua-lised after staining with Ethidium Bromide (1 mg/ml), and recorded using a gel documentation system (Alpha Innotech Corp., San Leandro, CA, USA).
For one-dimensional (standard) DGGE, 0.75 mm thick 10% polyacrylamide with identical denaturing gradient gels and a 10% nondenaturing polyacrylamide stacker, were poured. Combs used in DGGE contained multiple wells, allowing single fragment analysis. Conditions were identical to the second dimension mentioned above.
Fragments not clearly visible on TDGS and fragments with variants identi®ed by TDGS were ampli®ed using fragment speci®c primers and run on DGGE (Figure 3) .
Nucleotide sequencing
Fragments of interest were ampli®ed using non-GC-clamp primers. Products were gel and column puri®ed using the Wizard PCR-Prep kit (Promega, Madison, WI, USA). Sequence analysis was then carried out using the Applied Biosystems Prism Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer Corp., Norwalk, CT, USA). The products of cycle sequencing were electrophoresed on a 6% Long Ranger gel (FMC Bioproducts, Rockville, MD, USA) and analysed on an Applied Biosystems Model 373A automated DNA sequencer (Perkin-Elmer Corp.).
Sequences were compared against human mitochondrial DNA sequence, GENBANK accession #J01415 as well as a comprehensive mitochondrial databank, MITOMAP (1999) . 
